Medicare and GLP-1s: the $50 Bridge That Opened in July

The answer to “does Medicare cover Wegovy” changed on 1 July 2026, and most pages answering it are still describing the old rules. Several GLP-1 drugs prescribed for weight are now paid for, leaving eligible beneficiaries a flat $50 a month, under a temporary arrangement called the Medicare GLP-1 Bridge.^[1]

It is not a permanent benefit and it is not Part D coverage in the ordinary sense — it deliberately runs outside the Part D payment structure, because the law that bars Medicare from covering weight-loss drugs has not changed.^[2] It runs until 31 December 2027.

Why a bridge, and not just coverage

Medicare has been barred by statute from covering drugs used for weight loss. That is why a drug like Wegovy could be covered under Part D for cardiovascular risk reduction — an approved indication that is not weight loss — while the same drug for the same person, prescribed for weight, was not covered.

The Bridge is CMS working around that: a short-term demonstration operating outside the Part D benefit, which is how it can reach a weight-management indication the benefit itself cannot. ⚠ The corollary matters — if you already get a GLP-1 covered under your Part D benefit for an indication Part D allows, you stay there. The Bridge is not for you.

Who qualifies

You must be 18 or older and have Medicare drug coverage, and you must have met one of the following at the time GLP-1 therapy started — not necessarily today.^[1]

The plan types covered are broad: standalone drug plans (PDP), Medicare Advantage plans with drug coverage (MA-PD, including HMO, HMOPOS and local or regional PPO), Special Needs Plans, employer or union group waiver plans, and the LI NET program. It is nationwide, including all states and US territories.^[1]

Which drugs — and the restriction people will miss

Note also what is absent: Mounjaro and Ozempic are not on the list, which follows from the design — those carry diabetes indications, and a diabetes prescription is already a Part D matter rather than a Bridge one.

How to actually get it

1. Confirm you have Part D drug coverage of one of the qualifying plan types.
2. Check the criteria against when you started, not against today’s numbers, and gather what documents that.
3. Your prescriber sends the prescription to the pharmacy and completes prior authorization when asked. In 2026 CMS uses a single central processor for authorization, claims and pharmacy payment.^[2]
4. Your provider certifies the lifestyle requirement. They must confirm you are using the drug as part of a program focused on diet and exercise — a real condition of the program, not a formality.
5. Bring your Medicare number. The pharmacy may ask for it or for its last four digits.

$50 against the cash market

For anyone who qualifies, $50 a month undercuts the entire cash market. Across the 481 compounded semaglutide prices in this register the cheapest is $65 and the median is $189.99; across 435 tirzepatide prices the cheapest is $83 and the median is $258. Nothing in the compounded market reaches $50, and the Bridge supplies the approved product rather than a compounded preparation — which is the more meaningful difference of the two.

⚠ It ends on 31 December 2027, and CMS describes it as short-term. What follows is not settled on the current public record, so treat the $50 as a window rather than a permanent floor. Our cash-market guide covers what the alternative costs today.

Common questions